• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德国遗传性乳腺癌和卵巢癌联盟关于遗传性乳腺癌和卵巢癌风险基因种系序列变异分类的标准。

Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.

作者信息

Wappenschmidt Barbara, Hauke Jan, Faust Ulrike, Niederacher Dieter, Wiesmüller Lisa, Schmidt Gunnar, Groß Evi, Gehrig Andrea, Sutter Christian, Ramser Juliane, Rump Andreas, Arnold Norbert, Meindl Alfons

机构信息

Zentrum familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany.

Institut für Medizinische Genetik und Angewandte Genomik, Universität Tübingen, Tübingen, Germany.

出版信息

Geburtshilfe Frauenheilkd. 2020 Apr;80(4):410-429. doi: 10.1055/a-1110-0909. Epub 2020 Apr 21.

DOI:10.1055/a-1110-0909
PMID:32322110
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7174002/
Abstract

More than ten years ago, the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC) set up a panel of experts (VUS Task Force) which was tasked with reviewing the classifications of genetic variants reported by individual centres of the GC-HBOC to the central database in Leipzig and reclassifying them, where necessary, based on the most recent data. When it evaluates variants, the VUS Task Force must arrive at a consensus. The resulting classifications are recorded in a central database where they serve as a basis for ensuring the consistent evaluation of previously known and newly identified variants in the different centres of the GC-HBOC. The standardised VUS evaluation by the VUS Task Force is a key element of the recall system which has also been set up by the GC-HBOC. The system will be used to pass on information to families monitored and managed by GC-HBOC centres in the event that previously classified variants are reclassified based on new information. The evaluation algorithm of the VUS Task Force was compiled using internationally established assessment methods (IARC, ACMG, ENIGMA) and is presented here together with the underlying evaluation criteria used to arrive at the classification decision using a flow chart. In addition, the characteristics and special features of specific individual risk genes associated with breast and/or ovarian cancer are discussed in separate subsections. The URLs of relevant databases have also been included together with extensive literature references to provide additional information and cover the scope and dynamism of the current state of knowledge on the evaluation of genetic variants. In future, if criteria are updated based on new information, the update will be published on the website of the GC-HBOC ( https://www.konsortium-familiaerer-brustkrebs.de/ ).

摘要

十多年前,德国遗传性乳腺癌和卵巢癌联盟(GC-HBOC)设立了一个专家小组(VUS特别工作组),其任务是审查GC-HBOC各中心向莱比锡中央数据库报告的基因变异分类,并在必要时根据最新数据对其重新分类。VUS特别工作组在评估变异时必须达成共识。最终的分类记录在一个中央数据库中,作为确保GC-HBOC不同中心对先前已知和新发现的变异进行一致评估的基础。VUS特别工作组的标准化VUS评估是GC-HBOC建立的召回系统的关键要素。如果根据新信息对先前分类的变异进行重新分类,该系统将用于向由GC-HBOC中心监测和管理的家庭传递信息。VUS特别工作组的评估算法是使用国际公认的评估方法(IARC、ACMG、ENIGMA)编制的,并在此与用于通过流程图做出分类决定的基础评估标准一起呈现。此外,在单独的小节中讨论了与乳腺癌和/或卵巢癌相关的特定个体风险基因的特征和特点。还包括了相关数据库的网址以及大量文献参考,以提供更多信息,并涵盖基因变异评估当前知识状态的范围和动态性。未来,如果根据新信息更新标准,更新内容将在GC-HBOC的网站(https://www.konsortium-familiaerer-brustkrebs.de/)上发布。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/f62323aad006/10-1055-a-1110-0909-igfde02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/55388866e335/10-1055-a-1110-0909-igf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/152860162665/10-1055-a-1110-0909-igf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/07401a49b24c/10-1055-a-1110-0909-igfde01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/f62323aad006/10-1055-a-1110-0909-igfde02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/55388866e335/10-1055-a-1110-0909-igf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/152860162665/10-1055-a-1110-0909-igf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/07401a49b24c/10-1055-a-1110-0909-igfde01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a089/7174002/f62323aad006/10-1055-a-1110-0909-igfde02.jpg

相似文献

1
Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.德国遗传性乳腺癌和卵巢癌联盟关于遗传性乳腺癌和卵巢癌风险基因种系序列变异分类的标准。
Geburtshilfe Frauenheilkd. 2020 Apr;80(4):410-429. doi: 10.1055/a-1110-0909. Epub 2020 Apr 21.
2
Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.对近 7000 名疑似 HBOC 患者进行扩展种系基因检测的诊断产出率和临床相关性。
Eur J Hum Genet. 2023 Aug;31(8):925-930. doi: 10.1038/s41431-023-01380-2. Epub 2023 May 15.
3
Changes in classification of genetic variants in BRCA1 and BRCA2.BRCA1和BRCA2基因变异分类的变化。
Arch Gynecol Obstet. 2018 Feb;297(2):279-280. doi: 10.1007/s00404-017-4631-2. Epub 2018 Jan 4.
4
Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients.通过下一代测序多基因panel 在 BRCAX 患者中鉴定 DNA 损伤修复基因的种系致病性变异。
Clin Biochem. 2020 Feb;76:17-23. doi: 10.1016/j.clinbiochem.2019.11.014. Epub 2019 Nov 28.
5
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].[日本遗传性乳腺癌和卵巢癌的当前临床问题及近期趋势——HBOC的基因检测与降低风险手术]
Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9.
6
Implementing mainstream genetic counseling within the area-wide network of the German Consortium Hereditary Breast and Ovarian Cancer (GC-HBOC): Satisfaction of primary care providers with the provided state-of-the-art training by the Cologne Center.在德国遗传性乳腺癌和卵巢癌联合会(GC-HBOC)的区域网络内实施主流遗传咨询:初级保健提供者对科隆中心提供的最先进培训的满意度。
J Genet Couns. 2024 Feb;33(1):206-215. doi: 10.1002/jgc4.1870. Epub 2024 Feb 13.
7
Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.德国遗传性乳腺癌和卵巢癌联盟的共识建议
Breast Care (Basel). 2022 Apr;17(2):199-207. doi: 10.1159/000516376. Epub 2021 Jul 19.
8
Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.胚系失活变异的 BARD1 基因与早发性家族性乳腺癌相关,但与卵巢癌无关。
Breast Cancer Res. 2019 Apr 29;21(1):55. doi: 10.1186/s13058-019-1137-9.
9
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
10
Primary Prevention and Early Detection of Hereditary Breast Cancer.遗传性乳腺癌的一级预防与早期检测
Breast Care (Basel). 2023 Dec;18(6):448-454. doi: 10.1159/000533391. Epub 2023 Aug 14.

引用本文的文献

1
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores.乳腺癌多基因风险评分的临床应用指南。
Cancers (Basel). 2025 Mar 21;17(7):1056. doi: 10.3390/cancers17071056.
2
A Novel Element Insertion in Induces Exon Skipping in Suspected HBOC Patients.一种新型元件插入在疑似遗传性乳腺癌卵巢癌综合征(HBOC)患者中诱导外显子跳跃。
Hum Mutat. 2023 Apr 4;2023:6623515. doi: 10.1155/2023/6623515. eCollection 2023.
3
Reclassification of VUS in and using the new / ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system.

本文引用的文献

1
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction.在乳腺癌先证者中检测到的两个错义变体可阻止BRCA2与PALB2蛋白相互作用。
Front Oncol. 2018 Oct 25;8:480. doi: 10.3389/fonc.2018.00480. eCollection 2018.
2
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.家族性乳腺癌与 DNA 修复基因:GENESIS 研究中已知和新发现的易感基因的深入了解,及其对多基因panel 检测的意义。
Int J Cancer. 2019 Apr 15;144(8):1962-1974. doi: 10.1002/ijc.31921. Epub 2018 Nov 13.
3
Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
使用新的/ENIGMA轨迹集对[具体内容]和[具体内容]中的VUS进行重新分类,证明了ClinGen ENIGMA专家小组规范相对于标准ACMG/AMP分类系统的优越性。
Genet Med Open. 2025 Jan 7;3:101961. doi: 10.1016/j.gimo.2024.101961. eCollection 2025.
4
Joint analysis of germline genetic data from over 29,000 cases with suspected hereditary breast and ovarian cancer (HBOC) as part of the NASGE initiative.作为NASGE计划的一部分,对超过29000例疑似遗传性乳腺癌和卵巢癌(HBOC)病例的种系遗传数据进行联合分析。
Breast. 2025 Apr;80:103887. doi: 10.1016/j.breast.2025.103887. Epub 2025 Jan 20.
5
Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne.科隆家族性乳腺癌和卵巢癌中心的 TP53 种系变异家族的表型分析。
Cancer Med. 2024 Feb;13(3):e6920. doi: 10.1002/cam4.6920. Epub 2024 Jan 17.
6
Primary Prevention and Early Detection of Hereditary Breast Cancer.遗传性乳腺癌的一级预防与早期检测
Breast Care (Basel). 2023 Dec;18(6):448-454. doi: 10.1159/000533391. Epub 2023 Aug 14.
7
Prevalence of Pathogenic Germline Variants in Women with Non-Familial Unilateral Triple-Negative Breast Cancer.非家族性单侧三阴性乳腺癌女性中致病种系变异的患病率
Breast Care (Basel). 2023 May;18(2):106-112. doi: 10.1159/000528972. Epub 2023 Jan 6.
8
Diagnostic yield and clinical relevance of expanded germline genetic testing for nearly 7000 suspected HBOC patients.对近 7000 名疑似 HBOC 患者进行扩展种系基因检测的诊断产出率和临床相关性。
Eur J Hum Genet. 2023 Aug;31(8):925-930. doi: 10.1038/s41431-023-01380-2. Epub 2023 May 15.
9
Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania.西波美拉尼亚人口稀少地区的遗传性乳腺癌和卵巢癌服务机构
Healthcare (Basel). 2022 Oct 13;10(10):2021. doi: 10.3390/healthcare10102021.
10
Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer.男性乳腺癌患者中癌症易感性种系变异的患病率:德国遗传性乳腺癌和卵巢癌联盟的结果
Cancers (Basel). 2022 Jul 5;14(13):3292. doi: 10.3390/cancers14133292.
Panel 34 基因种系变异全景图谱和 5131 个 HBOC 家族的癌症风险估计。
Genet Med. 2018 Dec;20(12):1677-1686. doi: 10.1038/s41436-018-0005-9. Epub 2018 Jul 10.
4
A novel de novo germline variant aids in the classification of carboxy-terminal E-cadherin alterations predicted to escape nonsense-mediated mRNA decay.一种新的从头发生的种系变异有助于对预计逃避无义介导的mRNA衰变的羧基末端E-钙黏蛋白改变进行分类。
Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). doi: 10.1101/mcs.a003012. Print 2018 Aug.
5
Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.在常规诊断环境中对 5589 名 BRCA1/2 阴性乳腺癌指数患者进行基因面板检测:德国遗传性乳腺癌和卵巢癌联合会的研究结果。
Cancer Med. 2018 Apr;7(4):1349-1358. doi: 10.1002/cam4.1376. Epub 2018 Mar 9.
6
BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.BRIP1 功能丧失性突变可导致家族性卵巢癌风险增加,但不导致家族性乳腺癌。
Breast Cancer Res. 2018 Jan 24;20(1):7. doi: 10.1186/s13058-018-0935-9.
7
Predicting the Functional Impact of CDH1 Missense Mutations in Hereditary Diffuse Gastric Cancer.预测 CDH1 错义突变在遗传性弥漫性胃癌中的功能影响。
Int J Mol Sci. 2017 Dec 12;18(12):2687. doi: 10.3390/ijms18122687.
8
Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.与参考对照组相比,在多基因检测板上检测的大量临床确诊卵巢癌病例中的突变频率。
Gynecol Oncol. 2017 Nov;147(2):375-380. doi: 10.1016/j.ygyno.2017.08.030. Epub 2017 Sep 7.
9
Functionally Null Missense Mutation Associates Strongly with Ovarian Carcinoma.功能缺失性错义突变与卵巢癌强烈相关。
Cancer Res. 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.
10
The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.c.5096G>A p.Arg1699Gln(R1699Q)中等风险变异:ENIGMA 联盟的乳腺癌和卵巢癌风险评估及临床管理建议。
J Med Genet. 2018 Jan;55(1):15-20. doi: 10.1136/jmedgenet-2017-104560. Epub 2017 May 10.